Market closed
Tonix Pharmaceuticals/$TNXP
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Tonix Pharmaceuticals
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.
Ticker
$TNXP
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
81
Website
TNXP Metrics
BasicAdvanced
$115M
-
-$176.60
2.24
-
Price and volume
Market cap
$115M
Beta
2.24
52-week high
$672.00
52-week low
$6.76
Average daily volume
1.4M
Financial strength
Current ratio
6.5
Quick ratio
5.822
Long term debt to equity
3.601
Total debt to equity
5.818
Management effectiveness
Return on assets (TTM)
-30.62%
Return on equity (TTM)
-106.12%
Valuation
Price to revenue (TTM)
1.3
Price to book
0.56
Price to tangible book (TTM)
0.56
Price to free cash flow (TTM)
-0.215
Growth
Revenue change (TTM)
29.94%
What the Analysts think about TNXP
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Tonix Pharmaceuticals stock.
TNXP Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
TNXP Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
TNXP News
AllArticlesVideos
Tonix Pharmaceuticals Presented Data on Potential Mpox Vaccine TNX-801 at World Vaccine Congress Washington 2025
GlobeNewsWire·3 days ago
Tonix Pharmaceuticals Announces Oral Presentation and Panel Participation at the World Vaccine Congress Washington 2025
GlobeNewsWire·2 weeks ago
Tonix Pharmaceuticals and Makana Therapeutics Announce Collaboration Combining Tonix's Anti-CD40L Monoclonal Antibody (TNX-1500) with Makana's Genetically Engineered Organs in Preclinical and Clinical Xenotransplantation Studies
GlobeNewsWire·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Tonix Pharmaceuticals stock?
Tonix Pharmaceuticals (TNXP) has a market cap of $115M as of April 27, 2025.
What is the P/E ratio for Tonix Pharmaceuticals stock?
The price to earnings (P/E) ratio for Tonix Pharmaceuticals (TNXP) stock is 0 as of April 27, 2025.
Does Tonix Pharmaceuticals stock pay dividends?
No, Tonix Pharmaceuticals (TNXP) stock does not pay dividends to its shareholders as of April 27, 2025.
When is the next Tonix Pharmaceuticals dividend payment date?
Tonix Pharmaceuticals (TNXP) stock does not pay dividends to its shareholders.
What is the beta indicator for Tonix Pharmaceuticals?
Tonix Pharmaceuticals (TNXP) has a beta rating of 2.24. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.